New York, NY -- (SBWIRE) -- 12/27/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Hemispherx BioPharma, Inc (NYSEMKT:HEB), Silver Standard Resources Inc. (USA) (NASDAQ:SSRI)
Idenix Pharmaceuticals Inc (NASDAQ:IDIX) opened the session at $6.87 and closed the session at $6.93. The stock showed a positive performance of 1.61% in previous trading session. Traded with volume of 1.19 million shares in the prior session and the average volume of the stock remained 933,492.00 shares. Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication,
For How Long IDIX will fight for Profitability? Read This Trend Analysis report
Hemispherx BioPharma, Inc (NYSEMKT:HEB) opened the session at $0.25 and closed the session at $0.231. The stock showed a negative performance of -6.44% in previous trading session. Traded with volume of 1.17 million shares in the prior session and the average volume of the stock remained 1.66 million shares. The beta of the stock remained 1.76. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza.
Why Should Investors Buy HEB After the Recent Fall? Just Go Here and Find Out
Silver Standard Resources Inc. (USA) (NASDAQ:SSRI) the stock advanced 1.62% and finished the session at $6.89. Traded with volume of 1.15 million shares in the prior session and the average volume of the stock remained 1.70 million shares. The beta of the stock remained 1.23. Silver Standard Resources Inc. is a silver resource company. The Company’s properties are located in six countries in the Americas. The Company is focused on operating and producing silver from the Pirquitas Mine, which is located in the Province of Jujuy, Argentina, and on advancing the Pitarrilla Project in Durango State, Mexico as well as the San Luis Project in Ancash Department, Peru. In addition, the Company continues to advance its portfolio of mineral projects and properties, which are at various stages of exploration and development.
Will SSRI Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)